View New Articles By
Damon Runyon staff spoke with NBC News journalist, author and cancer survivor Tom Brokaw after he provided remarks at our 2016 Annual Breakfast. The following blog post was edited and condensed from that interview.
DR: Thank you for attending our 2016 Annual Breakfast.
TB: I was very impressed with the whole organization. I had known kind of broadly about the organization, but that was an impressive breakfast.
Philippe Soriano, PhD, Professor, Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai
I have been on the Damon Runyon Fellowship Awards Committee for three years and as a developmental biologist, who studies signaling pathways in mouse embryos, I do not strictly work on cancer. However, the Damon-Runyon Fellows are all very bright minds and are curious about all areas of science, so it was really fun to interact with them at the Fellows Retreat in San Jose, CA, from September 25-28, 2016.
Lorraine Egan, President & Chief Executive Officer, Damon Runyon Cancer Research Foundation
A recent article in Nature, “The Unsung Heroes of CRISPR,” highlights the special role of young scientists in research breakthroughs. They are “unsung,” because they rarely get the credit they deserve for being important drivers of innovation in research. But they are crucial to progress against cancer and other biomedical research.
It made me think of Lin Manuel Miranda, the celebrated creator of Hamilton, who won his first Tony in 2008, when he was 28. He is a classic example of a young person breaking the mold. History is replete with stories of bold innovation by young minds. Take Steve Jobs and Bill Gates to name two other contemporary examples. The same is true in biomedical research. In fact, the majority of Nobel Prizes in science have gone to individuals who made their prize-winning discovery before they were 40.
Yung S. Lie, PhD, Deputy Director and Chief Scientific Officer, Damon Runyon Cancer Research Foundation
Public support for basic scientific research is essential, as it can help insure that brilliant young people continue to enter the sciences and dedicate their careers to cancer research. It can also insure that there will always be another Bill Kaelin in the pipeline.
Bill is a trailblazing physician-scientist at the Dana-Farber Cancer Institute, a member of our Board of Directors, and a winner of the 2016 Albert Lasker Basic Medical Research Award for his work on the pathway by which cells sense and adapt to changes in oxygen levels. The Boston Globe lauded the significance of Bill’s contributions to science and observed that, “This work on oxygen sensing has led to the development of potential drugs for heart attack, stroke, and kidney cancer, as well as possible treatments for anemia and retinopathy of prematurity, a condition that can blind premature infants.”
Lorraine Egan, President & Chief Executive Officer, Damon Runyon Cancer Research Foundation
CONNECT
1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006
